Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis

作者：Dalloneau Emilie; Baroukh Nadine; Mavridis Konstantinos; Maillet Agnes; Gueugnon Fabien; Courty Yves; Petit Agnes; Kryza Thomas; Del Rio Maguy; Guyetant Serge; Castaneda Diana Carolina Cadena; Dhommee Christine; Arnoult Christophe; Scorilas Andreas; Gouilleux Gruart Valerie; Heuze Vourc'h Nathalie^*

来源：Oncotarget, 2016, 7(34): 54415-54429.

DOI：10.18632/oncotarget.10074

• FcRn
• non-small cell lung cancer
• prognosis
• marker
• antitumor immunity

Lung cancer is the leading cause of cancer-related death worldwide. Although the recommended tumor, node and metastasis (TNM) classification and stage determination are important to select therapeutic options for patients with non-small cell lung carcinoma (NSCLC), additional molecular markers are required to indicate the prognosis, in particular within a specific stage, and help with the management of patients.
Because neonatal Fc receptor (FcRn) has recently been involved in colon cancer immunosurveillance, we measured its expression in non-cancerous and NSCLC lung tissues and evaluated its prognostic value in overall survival for patient with NSCLC. FcRn expression was determined at both mRNA and protein levels on cancerous and adjacent non-cancerous tissues from 80 NSCLC patients. In NSCLC, FcRn was mainly found in resident and tumor infiltrating immune cells. The corresponding mRNA and protein were significantly less abundant in lung tumor than non-cancerous tissue. Moreover, analysis of our cohort and datasets from the public data bases show that FCGRT mRNA down-regulation is a robust and independent, unfavorable predictive factor of NSCLC patient survival. We conclude that FCGRT mRNA expression may be a useful additional marker for immunoscoring, reflecting tumor immune system, and help in the decision-making process for NSCLC patients.

• 出版日期2016-8-23